Blog
RSS FeedPosted by Michael Wonder on 10 Jan 2023
Four types of bias in medical AI are running under the FDA’s radar
9 January 2023 - Although artificial intelligence is entering health care with great promise, clinical artificial intelligence tools are prone ...
Posted by Michael Wonder on 21 Nov 2022
Adjustment for baseline characteristics in randomised clinical trials
17 November 2022 - The purpose of randomisation in clinical trials is to ensure that there are no systematic differences between ...
Posted by Michael Wonder on 31 Aug 2022
Reproducibility of real world evidence studies using clinical practice data to inform regulatory and coverage decisions
31 August 2022 - Studies that generate real world evidence on the effects of medical products through analysis of digital data ...
Posted by Michael Wonder on 23 Mar 2022
Instrumental variables and heterogeneous treatment effects
22 March 2022 - A randomised clinical trial can be used to estimate the average treatment effect for a population. ...
Posted by Michael Wonder on 15 Mar 2022
Collider bias
14 March 2022 - Bias is a systematic, non-random error in the estimation of a treatment effect or the effect of ...
Posted by Michael Wonder on 26 Oct 2021
Strengthening the reporting of observational studies in epidemiology using Mendelian randomisation: the STROBE-MR Statement
26 October 2021 - An international expert committee, informed by the methodological framework for guideline development of the Enhancing the Quality ...
Posted by Michael Wonder on 04 Aug 2021
Interpreting the results of intention to treat, per protocol and as treated analyses of clinical trials
3 August 2021 - Non-adherence in a randomised clinical trial occurs when study participants do not follow the randomly assigned treatment ...
Posted by Michael Wonder on 17 Feb 2021
Immortal time bias in observational studies
16 February 2021 - Observational studies are commonly used to evaluate the association between a risk factor or “exposure” and the ...
Posted by Michael Wonder on 03 Aug 2020
Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov
27 July 2020 - The coronavirus disease 2019 (COVID-19) pandemic has led to a massive activation of clinical research. ...
Posted by Michael Wonder on 31 Jul 2020
Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomised harmony
31 July 2020 - Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, substantial effort is being directed toward ...
Posted by Michael Wonder on 02 Jul 2020
Regression discontinuity design
2 July 2020 - The method is used to study the outcomes related to an abrupt change when it is not ...
Posted by Michael Wonder on 15 Jun 2020
The pandemic claims new victims: prestigious medical journals
14 June 2020 - Two major study retractions in one month have left researchers wondering if the peer review process is ...
Posted by Michael Wonder on 05 May 2020
Overlap weighting: a propensity score method that mimics attributes of a randomised clinical trial
5 May 2020 - Evidence obtained from clinical practice settings that compares alternative treatments is an important source of information about ...
Posted by Michael Wonder on 18 Apr 2020
Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis
16 April 2020 - Everyone wants new treatments and vaccines to address the devastation of coronavirus disease 2019 (COVID-19). ...
Posted by Michael Wonder on 14 Mar 2020
Why test for proportional hazards?
13 March 2020 - The Cox proportional hazards model, introduced in 1972, has become the default approach for survival analysis in ...